SG11202109535SA - Cd3 binding molecules - Google Patents

Cd3 binding molecules

Info

Publication number
SG11202109535SA
SG11202109535SA SG11202109535SA SG11202109535SA SG 11202109535S A SG11202109535S A SG 11202109535SA SG 11202109535S A SG11202109535S A SG 11202109535SA SG 11202109535S A SG11202109535S A SG 11202109535SA
Authority
SG
Singapore
Prior art keywords
binding molecules
molecules
binding
Prior art date
Application number
Other languages
English (en)
Inventor
Loo Pieter Fokko Van
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202109535SA publication Critical patent/SG11202109535SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202109535S 2019-03-29 2020-03-27 Cd3 binding molecules SG11202109535SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166345 2019-03-29
EP19200931 2019-10-01
PCT/NL2020/050214 WO2020204708A1 (en) 2019-03-29 2020-03-27 Cd3 binding molecules

Publications (1)

Publication Number Publication Date
SG11202109535SA true SG11202109535SA (en) 2021-10-28

Family

ID=70057206

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109535S SG11202109535SA (en) 2019-03-29 2020-03-27 Cd3 binding molecules

Country Status (12)

Country Link
US (1) US20220356251A1 (pt)
EP (1) EP3947456A1 (pt)
JP (2) JP2022527935A (pt)
KR (1) KR20210145136A (pt)
AU (1) AU2020254215A1 (pt)
BR (1) BR112021018632A2 (pt)
CA (1) CA3133624A1 (pt)
IL (1) IL286013A (pt)
MX (1) MX2021010877A (pt)
SG (1) SG11202109535SA (pt)
TW (1) TW202039578A (pt)
WO (1) WO2020204708A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4238992A1 (en) * 2022-03-01 2023-09-06 Technische Universität Darmstadt Two in one - antibodies binding to egfr/pd-l1-double positive cells
WO2023165813A1 (en) * 2022-03-01 2023-09-07 Technische Universität Darmstadt "two-in-one"-antibodies binding to egfr/pd-l1-double positive cells
US20240132615A1 (en) 2022-05-05 2024-04-25 Ichnos Sciences SA CD3/BCMA/CD38 Trispecific Antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2965865C (en) 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
JP5139800B2 (ja) * 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
WO2009157771A2 (en) 2008-06-27 2009-12-30 Merus B.V. Antibody producing non-human mammals
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
CA2791109C (en) * 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
SG10201607369QA (en) 2012-04-20 2016-10-28 Merus Nv Methods and means for the production of ig-like molecules
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
HUE042040T2 (hu) 2012-09-27 2019-06-28 Merus Nv Bispecifikus IGG antitestek mint T-sejt kapcsolók
WO2017010874A1 (en) * 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
CN109219618B (zh) * 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
TW202003569A (zh) 2018-03-30 2020-01-16 荷蘭商美勒斯公司 多價抗體

Also Published As

Publication number Publication date
WO2020204708A1 (en) 2020-10-08
JP2023179541A (ja) 2023-12-19
BR112021018632A2 (pt) 2021-11-23
TW202039578A (zh) 2020-11-01
JP2022527935A (ja) 2022-06-07
US20220356251A1 (en) 2022-11-10
KR20210145136A (ko) 2021-12-01
AU2020254215A1 (en) 2021-09-30
CA3133624A1 (en) 2020-10-08
EP3947456A1 (en) 2022-02-09
MX2021010877A (es) 2021-10-22
IL286013A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
IL290517A (en) cd3 binding antibodies
IL263840A (en) cd3 binding antibodies
IL283635A (en) Anti-cd3 binding molecules and their uses
IL277848A (en) HER2-targeting antigen-binding molecules containing 4-1BBL
GB201901306D0 (en) Multi-domain binding molecules
IL286013A (en) cd3 binding molecules
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
IL287555A (en) binding compounds
GB201811410D0 (en) OX40 Binding molecules
IL289415A (en) Claudin-6 binding molecules and their use
IL284926A (en) CD3-specific binding molecules
IL292698A (en) Amino-terminated scfv multispecific binding molecules
GB201811408D0 (en) CD137 Binding Molecules
EP3941947A4 (en) ANTI-HER2 BINDING MOLECULES
EP3781204A4 (en) BINDING MOLECULES
IL288561A (en) gal9-binding molecules with immunosuppressive activity
IL288562A (en) Activating gal9 binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB202010329D0 (en) Specific binding molecules
GB201912657D0 (en) Binding members
GB201803178D0 (en) Specific binding molecules for htert
GB201914468D0 (en) Binding Molecules
GB201912030D0 (en) Binding molecules
GB201915282D0 (en) Specific binding molecules
GB201906872D0 (en) Binding molecules